Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies

RATIONALE & OBJECTIVE: Chronic kidney disease–associated pruritus (CKD-aP) in patients treated by hemodialysis (HD) impairs quality of life (QoL). Difelikefalin, a selective κ-opioid receptor agonist, decreased the intensity of CKD-aP in patients undergoing HD. This pooled analysis evaluated dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Topf, Joel, Wooldridge, Thomas, McCafferty, Kieran, Schömig, Michael, Csiky, Botond, Zwiech, Rafal, Wen, Warren, Bhaduri, Sarbani, Munera, Catherine, Lin, Rong, Jebara, Alia, Cirulli, Joshua, Menzaghi, Frédérique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396406/
https://www.ncbi.nlm.nih.gov/pubmed/36016762
http://dx.doi.org/10.1016/j.xkme.2022.100512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396406/
https://www.ncbi.nlm.nih.gov/pubmed/36016762
http://dx.doi.org/10.1016/j.xkme.2022.100512

Ejemplares similares